Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BCR-ABL gene variants

J V Melo1

  • 1Department of Haematology, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Bailliere'S Clinical Haematology
|June 1, 1997
PubMed
Summary
This summary is machine-generated.

The BCR-ABL hybrid gene drives most CML cases, with varying fusion protein sizes (p210, p190, p230) linked to specific disease subtypes and breakpoints. Rare variants and Ph-negative CML present unique challenges.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models.

Oncogenesis·2014
Same author

Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients.

Leukemia·2013
Same author

Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells.

Leukemia·2012
Same author

Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5.

Leukemia·2012
Same author

SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function.

Leukemia·2012
Same author

Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia.

Cell death & disease·2011
Same journal

Current status of stem cell therapy and prospects for gene therapy for the disorders of globin synthesis.

Bailliere's clinical haematology·2000
Same journal

Pharmacological therapy.

Bailliere's clinical haematology·2000
Same journal

Prenatal diagnosis and screening of the haemoglobinopathies.

Bailliere's clinical haematology·2000
Same journal

Sickle cell disease: clinical management.

Bailliere's clinical haematology·2000
Same journal

Pathophysiology of sickle cell disease.

Bailliere's clinical haematology·2000
Same journal

Thalassaemia: clinical management.

Bailliere's clinical haematology·2000
See all related articles

Area of Science:

  • Molecular Biology
  • Hematology
  • Oncology

Background:

  • The t(9;22) translocation creates the BCR-ABL hybrid gene, a hallmark in over 95% of Chronic Myeloid Leukemia (CML) patients.
  • BCR-ABL fusion proteins vary in size (p210, p190, p230) based on breakpoints within the BCR gene's major (M-bcr), minor (m-bcr), and micro (mu-bcr) regions.
  • The p210 BCR-ABL (M-bcr) is most common in CML, while p190BCR-ABL (m-bcr) is linked to Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).

Purpose of the Study:

  • To delineate the spectrum of BCR-ABL gene variants and their associated clinical phenotypes in leukemia.
  • To clarify the molecular basis of CML and related hematological malignancies.
  • To understand the implications of different BCR-ABL fusion types and breakpoints on disease presentation.

Main Methods:

Related Experiment Videos

  • Molecular analysis of the BCR-ABL fusion gene and its transcripts.
  • Characterization of breakpoint cluster regions (M-bcr, m-bcr, mu-bcr).
  • Correlation of specific BCR-ABL variants (e.g., p210, p190, p230) with clinical features and subtypes (CML, Ph+ ALL, CMML, CNL).

Main Results:

  • The p210 BCR-ABL (M-bcr) with b3a2/b2a2 junctions is prevalent in CML, with b3a2 potentially linked to thrombocytosis.
  • p190BCR-ABL (m-bcr) is primarily associated with Ph+ ALL, but rare CML cases show monocytic features (CMML-like).
  • p230 BCR-ABL (mu-bcr) is rare in CML, associated with Chronic Neutrophilic Leukemia (CNL) and/or marked thrombocytosis. Exceptional cases involve unusual breakpoints or intronic insertions.

Conclusions:

  • BCR-ABL gene variants and breakpoint locations significantly influence the clinical phenotype of leukemia, differentiating CML, Ph+ ALL, and other myeloid disorders.
  • While the reciprocal ABL-BCR gene is transcribed in many CML patients, its functional role remains unelucidated.
  • Ph-negative CML encompasses both BCR-ABL positive cases detectable by molecular methods and genuinely BCR-ABL negative atypical disease presentations.